Stay current with the latest press releases from within the industry.
Release issued 19th May 2005
PDS are delighted to announce that the range of regulatory services has recently expanded to include a new pharmacovigilance service. There has recently been a substantial change in the way in which the pharmacovigilance responsibilities of the Marketing Authorisation Holder (MAH) are regulated by the MHRA.
A responsible Qualified Person for pharmacovigilance must be named on the Marketing Authorisation (MA), and the MAH must have written procedures in place for the reception, tracking and reporting of adverse reactions onto a validated database. The MAH also has to perform a weekly search of the published literature to identify any adverse reaction reports that have appeared, and to report them to the MHRA. The MHRA is now actively inspecting MA holders for compliance with the new regulations, and have made it clear that they will take legal action for non-compliance. PDS has recruited the services of an experienced Qualified Person for pharmacovigilance, which will enable clients to be compliant with the requirements of the MHRA. The Director of Regulatory Affairs, Paul Sugden, welcomes informal enquiries relating to this new offering.
If you want to find out more about the company visit Pharmaceutical Development Services Ltd profile.
(18th October 2011) Working demonstration of the Gamlen Tablet Press planned for AAPS Exposition
(30th August 2011) GAMLEN TABLETING DEMONSTRATES NOVEL TABLET PRESS AT PHARMSCI 2011
(22nd March 2011) PharmaTraining React to Increasing Importance of SCM
(21st February 2011) Live demonstration and launch of the Gamlen Tablet Press
Clients in focus...